Description
Bone marrow aspirate concentrate (BMAC) has been utilized as an adjuvant therapy during hip arthroscopy to treat chondral damage; however, the literature lacks longitudinal follow-up tracking its effect beyond two years. Thus, the purpose of this study was to present minimum three-year functional outcomes in patients undergoing acetabular labral repair with BMAC augmentation to add to the growing body of work that describes the full scope of the orthobiologic’s healing potential in the hip.
